Chronic obstructive pulmonary disease future or investigational therapies: Difference between revisions
No edit summary |
m (Bot: Removing from Primary care) |
||
| Line 13: | Line 13: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WikiDoc Help Menu}} | |||
{{WikiDoc Sources}} | |||
[[Category:Pulmonology]] | [[Category:Pulmonology]] | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
Latest revision as of 20:58, 29 July 2020
|
Chronic obstructive pulmonary disease Microchapters |
|
Differentiating Chronic obstructive pulmonary disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Chronic obstructive pulmonary disease future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Chronic obstructive pulmonary disease future or investigational therapies |
|
FDA on Chronic obstructive pulmonary disease future or investigational therapies |
|
CDC on Chronic obstructive pulmonary disease future or investigational therapies |
|
Chronic obstructive pulmonary disease future or investigational therapies in the news |
|
Blogs on Chronic obstructive pulmonary disease future or investigational therapies |
|
Directions to Hospitals Treating Chronic obstructive pulmonary disease |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Omodamola Aje B.Sc, M.D. [2]
Future or Investigational Therapies
Trial Supportive Data
Use of long acting anticholinergics like Tiotropium have shown a reduction in frequency of COPD exacerbations, hospitalization and improvement in quality of life when compared with placebo [1], [2], [3]. However, these drugs didn't show any improvement in FEV1 or mortality. Additionally, two recently conducted large randomized trials compared tiotropium (anticholinergics) with salmeterol (long acting beta agonist)and placebo. Both the studies showed increased benefits in lung function tests, symptoms and quality of life with tiotropium when compared to salmeterol [2], [3]. Other studies showed tiotropium to decrease the number of exacerbation when compared with salmeterol [3].
Progress Towards a Non-Surgical Cure
With the discovery of multipotent lung stem cells in 2011, a new treatment option may soon become available. Scientists injected human lung stem cells into mice with damaged lungs. The stem cells formed human bronchioles, alveoli, and pulmonary vessels integrated structurally and functionally with the damaged mouse organ. The May 2011 report in the New England Journal of Medicine [4] concluded that human lung stem cells "have the undemonstrated potential to promote tissue restoration in patients with lung disease".
References
- ↑ Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW, Witek T (2002). "A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease". The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 19 (2): 217–24. PMID 11866001. Retrieved 2012-03-21. Unknown parameter
|month=ignored (help) - ↑ 2.0 2.1 Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ, Kesten S, Towse L (2002). "A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol". Chest. 122 (1): 47–55. PMID 12114338. Retrieved 2012-03-21. Unknown parameter
|month=ignored (help) - ↑ 3.0 3.1 3.2 Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L, Cornelissen PJ (2002). "Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium". The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology. 19 (2): 209–16. PMID 11871363. Retrieved 2012-03-21. Unknown parameter
|month=ignored (help) - ↑ "Evidence for Human Lung Stem Cells". New England Journal of Medicine. Retrieved 07-12-2011. Check date values in:
|accessdate=(help)